Navigation Links
ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin,Conjugate Data Presented at American Diabetes Association Annual,Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB) today announced that data relating to its proprietary PC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment of Type 2 diabetes will be presented at the 67th Scientific Sessions of the American Diabetes Association (ADA) to be held June 22-26, 2007 in Chicago, IL. The ADA's annual Scientific Sessions meeting is one of the largest gatherings of health care professionals involved in diabetes research and the delivery of diabetes care.

"These encouraging results from our Phase I/II multiple-dose clinical studies demonstrate that our PC-DAC(TM):Exendin-4 Albumin Conjugate is a well-tolerated and effective therapy," said Mark D. Perrin, President and CEO. "The data was further evidence of our compound's potential to become a once-weekly treatment for Type 2 diabetes."

The study titled "PC-DAC(TM):Exendin-4 (CJC-1134-PC) Demonstrates Safety and Efficacy as an Adjunct Therapy to Metformin: A Randomized, Double-Blind, Placebo-Controlled, One Month Phase I/II Study in 70 Patients with Type 2 Diabetes Mellitus", authored by Maggie Wang et al., was featured as a late breaking abstract. Seventy patients were enrolled in US and Canada and randomized to 1 mg, 2mg, 3mg of PC-DAC(TM):Exendin-4 or placebo treatment groups. All three treatment groups experienced reductions in fasting plasma glucose that were statistically significant versus baseline (p less than 0.005) and versus placebo (p less than 0.03) over the 5-week treatment period. Median HbA1c values decreased from baseline by 0.7%, 0.8% and 0.9% in the 1mg, 2mg, and 3mg groups, respectively, at the end of the study (Day 63) and were statistically significant (p less than 0.03 by ANCOVA) between pooled active patients (n=52) and placebo (n=18). There was no significant change in weight in the treatment cohorts (baseline 81-85kg) at the end of the treatment period. Generally low-titer antibodies were de tected in 11/52 treated patients. The drug was well-tolerated with no drug-related serious adverse events during the study.

In addition, the study titled "Safety and Pharmacodynamics of CJC-1134-PC, a Novel GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study", authored by Maggie Wang et al., was also featured as a poster session. This study evaluated the safety and efficacy of escalating single doses of CJC-1134-PC in 58 patients who had discontinued their oral antidiabetic agents for greater than or equal to 1 week and were randomized to either active drug or placebo in 6 escalating cohorts (PC-DAC(TM):Exendin-4 from 0.31mg to 5.0mg). Doses of greater than or equal to 1.25mg produced rapid and long-lasting reductions in mean daily glucose and fasting plasma glucose levels, persisting for at least 7 days after the single injection. In a separate cohort of 16 patients (12 active and 4 placebo) treated with either a single dose of 3mg PC-DAC(TM):Exendin-4 or placebo, a mean reduction in body weight of 2.5 kg (vs. 1.2 kg for placebo) was observed at the end of the 3-week in-clinic stay on a controlled diet. No significant safety or tolerability issues were reported at dose levels up to 3 mg.

Abstracts for the event can be found on the ADA's website at http://scientificsessions.diabetes.org

About PC-DAC(TM):Exendin-4

Exendin-4, like Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide and an agonist for the GLP-1 receptor. Exendin-4 decreases glucagon and increases insulin secretion in a glucose-dependent manner. Exendin-4 may stimulate beta-cell proliferation, restore beta-cell sensitivity to glucose, delay gastric emptying, and increase peripheral sensitivity to glucose. The clinical util ity of Exendin-4 is somewhat limited by its relatively short half-life in plasma. Developed with ConjuChem's proprietary PC-DAC(TM) technology, PC-DAC(TM):Exendin-4 is a modified Exendin-4 analogue that is covalently bound to recombinant human albumin (Recombumin(R), provided by Novozymes Delta Limited). Data from Phase I/II clinical studies have demonstrated that the preformed albumin-peptide conjugate has a much longer half-life than the peptide alone. The product is a highly soluble liquid formulation that is injectable in a small volume with a small gauge needle.

About ConjuChem

ConjuChem, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic DAC(TM) and PC-DAC(TM) Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide. Detailed descriptions of the Company can be viewed on the Company's website http://www.conjuchem.com.

-30-

/For further information: Lennie Ryer, CA, Vice President Finance, CFO, ConjuChem Biotechnologies Inc., (514) 844-5558 ext 224, mpolonsky@equicomgroup.com


'"/>




Related medicine technology :

1. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
2. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Augmedix, the nation,s leading smartglass-based ... closed a $23 million strategic round of funding ... company seeks to rehumanize the physician patient relationship ... EHR documentation. The Augmedix core offering is a ... from 3 hours of mandated charting and documentation ...
(Date:12/8/2016)... --  Mederi Therapeutics Inc . has announced regulatory approval by CFDA and product launch ... gastroesophageal reflux disease (GERD). Continue Reading ... ... of Digestive Endoscopy, by Professor Jun Liu, Director of Endoscopy at Wuhan Union Hospital ... "We are very pleased that Mederi products are now ...
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 /PRNewswire/ ... a pharmaceutical company advancing technologies designed to address ... appointment of Chitra Edwin , Ph.D., RAC, ... Compliance. Dr. Edwin will provide leadership for all ... for regulatory approvals, preparation of regulatory submissions, serving ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... STAT courier is ... be a convenient service for Texas, they are expanding their presence in Dallas. One ... hiring spree that will bring new jobs to the Dallas and Forth Worth market. ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... soon after surgery as possible. With this in mind, SIGVARIS has created a ... or blood clot) during bed rest and provide the benefits of graduated compression ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael ... headquartered in Hamilton County, is embarking on a charity drive with the aim ... new homes for orphaned or neglected senior dogs in the Cincinnati region, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... serve communities in and around the greater Phoenix metropolitan region, is announcing a ... , The mission of the Homeless Youth Connection is to promote community awareness ...
Breaking Medicine News(10 mins):